Executive Chairman, President & CEO, Dr. Pravin Dugel shares exciting progress for our two SOL studies in wet AMD. These pivotal studies are not only designed to meet regulatory standards but also aim to deliver commercially meaningful data. Visit https://ow.ly/tMjJ50Ta89i to learn more. #OCUTX #SOL #wetAMD #RetinalDiseases
About us
Ocular Therapeutix, Inc. (NASDAQ:OCUL) is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology, ELUTYX™. Ocular Therapeutix has built a robust product pipeline of drug delivery solutions developed to reduce the complexity and burden of the current standard of care and position itself to become a leader in the ophthalmic space. Ocular Therapeutix has a commercially available drug product, DEXTENZA® (dexamethasone ophthalmic insert) 0.4 mg, for intracanalicular use. DEXTENZA is an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery and for the treatment of ocular itching associated with allergic conjunctivitis; the product is currently being marketed through a fully integrated specialty sales force. Ocular Therapeutix’s lead clinical program AXPAXLI™ (axitinib intravitreal implant), also referenced as laboratory code OTX-TKI, is currently being developed to treat wet AMD and diabetic retinopathy; other indications may also be pursued in due course. Other clinical programs include PAXTRAVA™ (travoprost intracameral implant), also referenced as laboratory code OTX-TIC, for intracameral injection, for the treatment of elevated intraocular pressure in primary open-angle glaucoma or ocular hypertension, OTX-CSI (cyclosporine ophthalmic insert) for intracanalicular use, for the chronic treatment of dry eye disease, and OTX-DED (dexamethasone ophthalmic insert) for intracanalicular use, for the short-term treatment of the signs and symptoms of dry eye disease.
- Website
-
http://www.ocutx.com
External link for Ocular Therapeutix, Inc.
- Industry
- Pharmaceutical Manufacturing
- Company size
- 51-200 employees
- Headquarters
- Bedford, MA
- Type
- Public Company
- Founded
- 2006
- Specialties
- ocular drug delivery, surgical sealants, sustained delivery, ophthalmic therapies, ophthalmology, optometry, retina, cataract, glaucoma, wet AMD, anti-vegf, and drug delivery
Locations
-
Primary
15 Crosby Drive
Bedford, MA 01730, US
-
36 Crosby Drive
Suite 101
Bedford, MA 01730, US
Employees at Ocular Therapeutix, Inc.
Updates
-
Join the Ocular Therapeutix team! #NowHiring #ClinicalOperations #OCUTX Click here to view the full job description: https://ow.ly/y1Qx50TEpiO Click here for a full list of open positions: https://ow.ly/MUq250TEpiM
-
Our Chief Scientific Officer, Dr. Jeff Heier, shares insights on treatment challenges faced by patients with #wetAMD and other retinal diseases. Learn how we're committed to improving vision for patients in the real world at https://www.ocutx.com/. #OCUTX #RetinalDiseases
-
Millions of people around the world lack access to basic eye care. Join us in making a difference by donating eyeglasses to the Lions Clubs International Recycle For Sight Program. Visit their website to learn more: https://ow.ly/zpJh50TBb05. #OCUTX #OcularGivesBack #RecycleForSight
-
Don't miss any DEXTENZA updates or information! Be sure to follow DEXTENZA on LinkedIn and X. LinkedIn: https://ow.ly/jRcg50T8Icx X (Twitter): https://ow.ly/yA0250T8Icv #OCUTX #DEXTENZA
-
In honor of #WorldRetinaDay this past weekend, we're highlighting the personal journey of Owen Bishop, VP of Market Access at Ocular Therapeutix, and the impact wet AMD has had on his family. Together, we can raise awareness and drive change for patients with retinal diseases. #OCUTX #wetAMD #RetinalDiseases
-
Did you know there are about 200,000 new cases of wet AMD diagnosed every year? If you or a loved one has been diagnosed with wet AMD, visit https://sol.ocutx.com/ to learn more about SOL, a clinical trial for an investigational treatment option. #OCUTX #SOL #wetAMD
-
What a fantastic experience at the 24th European Society of Retina Specialists (EURETINA) Congress in Barcelona, Spain! Our team was thrilled to connect with renowned retina specialists to explore the latest advancements in retinal disease treatments. Thank you to everyone who visited our booth to learn about our commitment to improving vision in the real world. #OCUTX #EURETINA24 #wetAMD #NPDR #RetinalDiseases
-
Join the Ocular Therapeutix team! #NowHiring #Finance #OCUTX Click here to view the full job description: https://ow.ly/vqfz50TwABU Click here for a full list of open positions: https://ow.ly/KNyr50TwABQ
-
We’re thrilled to be presenting at the UBS Virtual Ophthalmology Day 2024 next week! Listen in on the webcast here: https://ow.ly/Z9qa50TvqAt. $OCUL #OCUTX #RetinalDiseases #wetAMD #NPDR